Tobin Schilke - 31 Dec 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Dec 2023
Net transactions value
+$3,242
Form type
4
Filing time
03 Jan 2024, 16:48:58 UTC
Previous filing
15 Aug 2023
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $3,242 +434 +0.48% $7.47 91,735 31 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).